DEXA-BEAM Salvage Chemotherapy and High-Dose Chemotherapy Followed by Autologous Bone Marrow Transplantation in Hodgkin’s Disease
Patients with advanced stage Hodgkin’s disease (HD) who fail first-line therapy or relapse within the first 12 months after having achieved a complete remission with combination chemotherapy (and radiotherapy) generally have a poor prognosis [1,2]. In an effort to improve the results of salvage therapy in such patients the German Hodgkin Study Group has followed various treatment strategies most recently including a new chemotherapy regimen consisting of dexamethasone, BCNU, cytosine-arabinoside, and melphalan (DEXA-BEAM). Other poor-risk patients have received high-dose chemotherapy (HDCT) followed by autologous bone marrow transplantation (ABMT). We report early results of both conventional and high-dose chemotherapy and demonstrate that DEXA-BEAM chemotherapy followed by HDCT/ABMT has substantial antitumor activity but lacks severe toxicity in most instances.
KeywordsLymphoma Dexamethasone Doxorubicin Melphalan Cyclophosphamide
Unable to display preview. Download preview PDF.
- 1.Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita DT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10: 210–218PubMedGoogle Scholar
- 3.Hiddemann W, Schmitz N, Pfreundschuh M, Pflüger KH, Ollech-Chwoyka J, Tirier C, Maschmeyer G, Kirchner H, Wagner T, Koch P, Dahmen E, Fiedler W, Trümper L, Diehl V (1990) Treatment of refractory Hodgkin’s disease with high-dose cytosine arabinoside and mitoxantrone in combination. Cancer 66: 838–843PubMedCrossRefGoogle Scholar
- 5.Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffier M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and darcabazine (ABVD): A multicenter trial of the German Hodgkin’s Study Group. Cancer Treat Rep 71: 1203–1207PubMedGoogle Scholar
- 8.Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, McLaughlin P, Cabanillas F, Spitzer G (1989) Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 7: 179–185PubMedGoogle Scholar
- 9.Reece DE, Barnett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH, Klingemann HG, O’Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL (1991) Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 9: 1871–1879PubMedGoogle Scholar
- 10.Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, Cetto GL, Cimino R, Alessandrino EP, Brusamolino E, Santini G, Tura S, Mandelli F, Rizzoli V, Bernasconi C, Marmont AM (1988) High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin’s disease patients: An Italian Study Group report. J Clin Oncol 6: 1411–1416PubMedGoogle Scholar
- 11.Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP (1990) Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin’s disease and non-Hodgkin’s lymphoma: A dose-finding study. J Clin Oncol 8: 648–656PubMedGoogle Scholar